<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04139330</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-06-5</org_study_id>
    <nct_id>NCT04139330</nct_id>
  </id_info>
  <brief_title>NPC-06 to Acute Pain in Herpes Zoster</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Trial to Investigate the Proof of Concept of NPC-06 to Acute Pain in Herpes Zoster</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nobelpharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nobelpharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the efficiency of pain relief and the safety of&#xD;
      NPC-06 for the acute pain in herpes zoster in the placebo-controlled double-blind parallel&#xD;
      group trial, in addition to explore the effective concentration of NPC-06.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The eligible patients will be randomized into three groups, and will receive single doses of&#xD;
      NPC-06 (high dose and low dose) or placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 28, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The improvement of NRS (Numeric Rating Scale:Max10, Min0, higher scores mean a worse outcome) score</measure>
    <time_frame>120 minutes after first administration</time_frame>
    <description>The average change (slope) of NRS score at the time of evaluation, which is measured before the first administration, 30, 60, 90 and 120 minutes after the first administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The improvement of NRS (Numeric Rating Scale:Max10, Min0, higher scores mean a worse outcome) score</measure>
    <time_frame>120 minutes after first administration</time_frame>
    <description>The change of NRS score at the time of evaluation compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of NRS (Numeric Rating Scale:Max10, Min0, higher scores mean a worse outcome) score</measure>
    <time_frame>120 minutes after first administration</time_frame>
    <description>The ratio of subjects who improve 2 or more points compared to baseline at 120 minutes after first administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The improvement of QOL(EQ-5D-5L, Max 1.000, Min -0.111, higher scores mean a better outcome) score</measure>
    <time_frame>7 days</time_frame>
    <description>The change of QOL score at the time of evaluation compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Acute Pain in Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>NPC-06 (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse diluted NPC-06 18mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 18 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPC-06 (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infuse diluted NPC-06 12mg/kg solution with 3 to 4 times volume of saline. Administarate NPC-06 gradually (slowly) over 12 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NPC-06 (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Infuse NPC-06 (placebo) over 12 minutes or 18 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPC-06</intervention_name>
    <description>Infuse NPC-06 intravenously</description>
    <arm_group_label>NPC-06 (high dose)</arm_group_label>
    <arm_group_label>NPC-06 (low dose)</arm_group_label>
    <arm_group_label>NPC-06 (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 years old or over at the time of informed consent.&#xD;
&#xD;
          2. Both genders.&#xD;
&#xD;
          3. Patients who have acute rash (either erythema or papule or bulla or pustule, or more),&#xD;
             except who have crust more than 20% of entire rash at just before the time of the&#xD;
             first administration.&#xD;
&#xD;
          4. Patients who are administrated antiviral drug for herpes zoster at the time of the&#xD;
             first administration.&#xD;
&#xD;
          5. Patients who are administrated non-opioid analgesics(acetaminophen, NSAIDs) for herpes&#xD;
             zoster at the time of the first administration.&#xD;
&#xD;
          6. Patients who the NRS score at the time of below evaluation point is higher than 4.&#xD;
&#xD;
               -  120 minutes before the start of infusion.&#xD;
&#xD;
               -  Just before the start of infusion.&#xD;
&#xD;
          7. Patients who the therapeutic effect of non-opioid analgesics for herpes zoster has&#xD;
             been insufficient.&#xD;
&#xD;
          8. Patients who can admit to hospital for the all assessment duration from first&#xD;
             administration until next day (including hospitalized patient).&#xD;
&#xD;
          9. Patients or his/her guardian who give a written informed consent in understanding and&#xD;
             willingness after having received enough explanation regarding the study&#xD;
             participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who cannot evaluate NRS by themselves.&#xD;
&#xD;
          2. Patients who are suspected to intracranial pressure increase.&#xD;
&#xD;
          3. Patients who have epilepsy, serious psychiatric or serious neurological disease (i. e.&#xD;
             dementia, Parkinson disease and schizophrenic disorder) or consciousness disorder.&#xD;
&#xD;
          4. Patients who have malignant tumors (except for patients who have no signs of&#xD;
             recurrence under treatment) or patients who are under treatment for HIV or patients&#xD;
             who are receiving immunosuppressant.&#xD;
&#xD;
          5. Patients who have complicated idiopathic trigeminal neuralgia.&#xD;
&#xD;
          6. Patients who have other serious pain which may affect the evaluation of acute herpetic&#xD;
             pain.&#xD;
&#xD;
          7. Patients who are receiving opioids or steroids(systemic).&#xD;
&#xD;
          8. Patients who have sinus bradycardia or serious disturbance of conduction system.&#xD;
&#xD;
          9. Patients who have history of hypersensitivity against hydantoin compound.&#xD;
&#xD;
         10. Patients who are receiving tadalafil (for pulmonary hypertension), rilpivirine,&#xD;
             asunaprevir, daclatasvir, vaniprevir, macitentan or sofosbuvir.&#xD;
&#xD;
         11. Patients who are receiving medications for neuropathic pain, antidepressants,&#xD;
             antiarrhythmic drugs, N-methyl-D-aspartate receptor antagonists, muscle relaxants,&#xD;
             local anesthetics, an extract from inflammatory rabbit skin inoculated by vaccinia&#xD;
             virus, Chinese herbal medications for analgesia, vitamin B12.&#xD;
&#xD;
         12. Patients who are receiving amenamevir.&#xD;
&#xD;
         13. Patients who have meningitis or meningeal irritation signs.&#xD;
&#xD;
         14. Patients who have complications such as serious heart disease, hepatic function&#xD;
             disorder or renal function disorder which severity are considered by investigator as&#xD;
             grade 3 or more severe with reference to ''Concerning classification criteria for&#xD;
             seriousness of adverse drug reactions of medical agents'' .&#xD;
&#xD;
         15. Patients who are receiving fosphenytoin, phenytoin or ethotoin and combination drug&#xD;
             including these or have taken these drugs as adjuvant therapy for pain .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kawasaki Hospital</name>
      <address>
        <city>Okayama city</city>
        <state>Okayama</state>
        <zip>700-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

